HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Palandri, F. Search for Related Content PubMed PubMed Citation Articles by Palandri, F.

Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: comparison between complete cytogenetic responders treated in early and in late chronic phase

^* Department of Hematology/Oncology "L. and A. Seràgnoli" S. Orsola-Malpighi Hospital, University of Bologna, Bologna;
^° CEINGE Biotecnologie Avanzate and Department of Biochemistry and Medical Biotechnology, University of Naples Federico II, Naples;
^# Department of Clinical and Biological Science, University of Turin at Orbassano, Turin, Italy

Correspondence: Francesca Palandri, Institute of Hematology and Medical Oncology "L. and A. Seràgnoli", St. Orsola-Malpighi University Hospital, via Massarenti, 9, 40138 Bologna, Italy. Phone: international +39.051.6363680. Fax: international +39. 051.6364037. E-mail: francesca.palandri{at}libero.it

CML patients who obtain a complete cytogenetic response (CCgR) may harbor different degrees of molecular disease, which are associated with different progression-free survival. We have compared the pattern and the magnitude of the molecular response (MolR) of 54 early chronic phase (ECP) and of 115 late CP patients who achieved a stable CCgR with IM 400 mg/daily. ECP patients obtained earlier, higher and more sustained MMolR.